Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Executive Summary
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.
You may also be interested in...
Axsome Succeeds In Narcolepsy Phase III, But Is That Enough?
Analysts say reboxetine looks approvable for cataplexy related to narcolepsy, but debate how broadly the drug may be adopted in a generic-laden therapeutic space.
Lupin Looks To Next Generation In Narcolepsy With Tentative US Xywav Nod
Lupin may enjoy 180 days of market exclusivity for its proposed generic to Jazz’s next-generation Xywav treatment for sleep disorders.
Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.